A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment. The test was able to distinguish between patients with a good or poor prognosis, even within groups of patients already stratified by existing tests such as MammaPrint and Oncotype, as well as to extend its predictions to patients with more advanced or difficult-to-treat cancers. Read more here.
Study mentioned: Lee U, et al. A Prognostic Gene Signature for Metastasis-Free Survival of Triple Negative Breast Cancer Patients. PLoS ONE. 2013; 8(12): e82125.
No comments:
Post a Comment